Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00621244 · OUTCOME

Response as Per Investigator Assessment for Patients With Hodgkin's Lymphoma (HD)

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies · Source last updated 2021-01-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
3.5 years

What was measured

Response as per investigator assessment for patients include complete response, partial remission, stable disease, progressive disease (PD)/failure.

Analysis population: Full Analysis Set

Groups in this outcome

Arm 1, Group Y

panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week, as part of a 28-day treatment cycle. Group Y indications (MM, HL, and NHL) is a sub-arm, based on disease indication.

Arm 2, Group Y

panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle. Group Y indications (MM, HL, and NHL) is a sub-arm, based on disease indication.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm 1, Group Y22
Arm 2, Group Y10

Reported measurements

Complete response (CR)
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1, Group Y1Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y1Not reportedNot reportedNot reportedNot reported
Partial remission (PR)
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1, Group Y4Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y3Not reportedNot reportedNot reportedNot reported
Stable disease (SD)
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1, Group Y11Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y4Not reportedNot reportedNot reportedNot reported
Progressive disease (PD)/failure
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1, Group Y1Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y2Not reportedNot reportedNot reportedNot reported
Missing
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1, Group Y5Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
    title
    Complete response (CR)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        4
      2. group Id
        OG001
        value
        3
    title
    Partial remission (PR)
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        11
      2. group Id
        OG001
        value
        4
    title
    Stable disease (SD)
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        2
    title
    Progressive disease (PD)/failure
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        5
      2. group Id
        OG001
        value
        0
    title
    Missing
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    2. group Id
      OG001
      value
      10
    units
    Participants
description
Response as per investigator assessment for patients include complete response, partial remission, stable disease, progressive disease (PD)/failure.
groups
  1. description
    panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week, as part of a 28-day treatment cycle. Group Y indications (MM, HL, and NHL) is a sub-arm, based on disease indication.
    id
    OG000
    title
    Arm 1, Group Y
  2. description
    panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle. Group Y indications (MM, HL, and NHL) is a sub-arm, based on disease indication.
    id
    OG001
    title
    Arm 2, Group Y
param Type
NUMBER
population Description
Full Analysis Set
reporting Status
POSTED
time Frame
3.5 years
title
Response as Per Investigator Assessment for Patients With Hodgkin's Lymphoma (HD)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice